Regorafenib in Metastatic Colorectal Cancer : a Cohort Study in the Real-life Setting
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This is a largest cohort study aimed to estimate the overall survival of patients been
treated with regorafenib for metastatic colorectal cancer (mCRC) within the frame of a french
compassionate program.